Zacchaeus Anywaine

Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania

Zacchaeus Anywaine, Hilary Whitworth, Pontiano Kaleebu et al. · The Journal of Infectious Diseases · 2019 · 153 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +14

Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa

Houreratou Barry, Gaudensia Mutua, Hannah Kibuuka et al. · PLoS Medicine · 2021 · 69 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial

Zacchaeus Anywaine, Houreratou Barry, Omu Anzala et al. · PLoS Medicine · 2022 · 63 citations · Full text

Medicine, Infectious Diseases, Pediatrics +17

Discontinuing cotrimoxazole preventive therapy in HIV-infected adults who are stable on antiretroviral treatment in Uganda (COSTOP): A randomised placebo controlled trial

Zacchaeus Anywaine, Jonathan Levin, Ronnie Kasirye et al. · PLoS ONE · 2018 · 23 citations · Full text

Public Health, Pharmacotherapy, Preventive Medicine +17

Factors affecting mortality among HIV positive patients two years after completing recommended therapy for Cryptococcal meningitis in Uganda

Jonathan Kitonsa, Yunia Mayanja, Emmanuel Aling et al. · PLoS ONE · 2019 · 19 citations · Full text

Veterinary Medicine, Infectious Diseases, Pharmacotherapy +13